Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inspire Medical Systems (INSP) Interest & Investment Income (2017 - 2025)

Inspire Medical Systems' Interest & Investment Income history spans 9 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 27.95% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $17.5 million, down 24.57%, while the annual FY2025 figure was $17.5 million, 24.57% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $4.0 million at Inspire Medical Systems, roughly flat from $4.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $5.9 million in Q1 2024 and bottomed at $15000.0 in Q4 2021.
  • The 5-year median for Interest & Investment Income is $4.1 million (2023), against an average of $3.3 million.
  • The largest annual shift saw Interest & Investment Income plummeted 91.12% in 2021 before it skyrocketed 22360.0% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $15000.0 in 2021, then surged by 22360.0% to $3.4 million in 2022, then soared by 74.24% to $5.9 million in 2023, then decreased by 5.42% to $5.6 million in 2024, then dropped by 27.95% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for INSP's Interest & Investment Income are $4.0 million (Q4 2025), $4.0 million (Q3 2025), and $4.5 million (Q2 2025).